Boesch S T, Dobler G, Ramoner R, Corvin S, Thurnher M, Bartsch G, Klocker H
Department of Urology, University of Innsbruck, Innsbruck, Austria.
Prostate Suppl. 2000;9:34-41. doi: 10.1002/1097-0045(2000)45:9+<34::aid-pros8>3.0.co;2-y.
alpha1-adrenoceptor (alpha1-AR) antagonists, used to relieve the lower tract urinary symptoms (LUTS) in benign prostate hyperplasia (BPH) patients, are thought to act in inhibiting the contraction of stromal smooth muscle. An attempt was made using new technology to visualize and quantify the effect of alpha1-AR antagonists in a cell culture model of prostatic smooth muscle cells (SMC).
Prostatic smooth muscle cells cultured from human prostate tissue were treated with alpha1-AR agonists and antagonists. The effects on cell growth, cell contraction, differentiation status, and apoptosis were determined by means of an MTT cell viability assay, time-lapse video microscopy, RT-PCR analysis, and FACS analysis of annexin V/propidium iodide-stained cells, respectively.
Prostatic smooth muscle cells derived from prostate tissue expressed SMC-specific markers. They showed spontaneous contractions, and phenylephrine increased the percentage of contracting cells by 3-fold. alpha1-AR antagonists inhibited spontaneous as well as phenylephrine-induced contractions. Long-term treatment with doxazosin induced differentiation tended towards a contractile phenotype, as indicated by an increase of the ratio of smooth muscle heavy chain myosin subtypes SM2/SM1. There was, however, no effect on cell growth. High concentrations of antagonist (100 microM) induced apoptosis in about 80% of the treated SMC. This effect was not cell-type-specific and was also seen in skin fibroblasts and immortalized prostate epithelial cells.
In an easy-to-handle cell culture model of prostatic smooth muscle cells, the effects of alpha1-AR antagonists on cell contraction, growth, and differentiation can be investigated. The results indicate that in addition to inhibition of cell contraction, alpha1-AR antagonists have the potential to induce apoptosis.
α1肾上腺素能受体(α1-AR)拮抗剂用于缓解良性前列腺增生(BPH)患者的下尿路症状(LUTS),被认为通过抑制基质平滑肌收缩发挥作用。本研究尝试运用新技术在前列腺平滑肌细胞(SMC)的细胞培养模型中可视化并量化α1-AR拮抗剂的作用。
用人前列腺组织培养的前列腺平滑肌细胞分别用α1-AR激动剂和拮抗剂处理。分别通过MTT细胞活力测定、延时视频显微镜观察、RT-PCR分析以及对膜联蛋白V/碘化丙啶染色细胞的流式细胞术分析来确定其对细胞生长、细胞收缩、分化状态和凋亡的影响。
源自前列腺组织的前列腺平滑肌细胞表达SMC特异性标志物。它们表现出自发性收缩,去氧肾上腺素使收缩细胞的百分比增加了3倍。α1-AR拮抗剂抑制自发性以及去氧肾上腺素诱导的收缩。多沙唑嗪长期处理诱导分化倾向于收缩表型,这通过平滑肌重链肌球蛋白亚型SM2/SM1比例的增加得以体现。然而,对细胞生长没有影响。高浓度拮抗剂(100μM)在约80%的处理后的SMC中诱导凋亡。这种效应不是细胞类型特异性的,在皮肤成纤维细胞和永生化前列腺上皮细胞中也可见。
在易于操作的前列腺平滑肌细胞培养模型中,可以研究α1-AR拮抗剂对细胞收缩、生长和分化的影响。结果表明,除了抑制细胞收缩外,α1-AR拮抗剂还有诱导凋亡的潜力。